From the Wall Street Journal:

Geron Corp., a Menlo Park, Calif., biotechnology company, is expected to announce Friday that it received a green light from the agency to mount a study of its stem-cell treatment for spinal cord injuries in up to 10 patients. The announcement caps more than a decade of advances in the company’s labs and comes on the cusp of a widely expected shift in U.S. policy toward support of embryonic stem-cell research after years of official opposition.

Obviously stem cell research should not be forbidden. It’s good to see this important avenue of research is back on track. Hopefully big discoveries will be made before another conservative president forbids it.

This entry was posted on Friday, January 23rd, 2009 at 10:23 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.